Changes in serum IGF‑1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions

Cao,Hong; Jin,Chunhui; Huang,Defang; Liu,Chao; Sun,Daoqi; Tan,Cheng; Zhu,Xiaoming; Fei,Yajun

doi:10.3892/mmr.2013.1339

Changes in serum IGF‑1 level and tumor VEGF expression in mice with colorectal cancer under hyperglycemic conditions

Authors:
- Hong Cao
- Chunhui Jin
- Defang Huang
- Chao Liu
- Daoqi Sun
- Cheng Tan
- Xiaoming Zhu
- Yajun Fei
View Affiliations

Affiliations: Department of Endocrinology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, P.R. China, Department of Oncology, Wuxi Traditional Chinese Medicine Hospital, Wuxi, Jiangsu 214001, P.R. China, Department of Endocrinology, The Third Affiliated Hospital of Nantong University, Wuxi, Jiangsu 214001, P.R. China, Department of Endocrinology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, Jiangsu 210028, P.R. China, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/mmr.2013.1339
Pages: 1361-1365

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to observe the growth of transplanted tumors in mice with colorectal cancer (CRC) under hyperglycemic conditions and to detect the expression of vascular endothelial growth factor (VEGF) in these tumors. The study also aimed to observe the changes in serum insulin‑like growth factor‑1 (IGF‑1) levels and to determine whether type 2 diabetes mellitus (T2DM) was a risk factor for the progression and development of CRC. A mouse model of a transplanted colorectal tumor with T2DM was established to observe the changes in volume and size of the transplanted tumor. Mice were sacrificed at the end of the 5th week to determine the serum IGF‑1 level and VEGF expression in the tumor tissues. The tumor volume (1628.5±882 mm3) in the CRC‑DM group was larger than that in the CRC group (1950.2±726 mm3; P<0.05). The serum IGF‑1 level (105.33±32.32 ng/ml) was higher than that in the normal (69.83±25.57 ng/ml) and CRC groups (70.17±25.27 ng/ml; P<0.05). The VEGF expression in the tumor tissues of the CRC‑DM group(70.0±11.5%) was higher than that in the CRC group (42.9±7.5%; P<0.05). T2DM may be one of the causes for the promotion of CRC growth and its mechanism may be correlated with the increased IGF‑1 action observed in the blood that induces VEGF gene transcription, upregulates VEGF expression, causes tumor angiogenesis and thus leads to the occurrence and metastasis of tumors.

View Figures

View References

1	Larsson SC, Orsini N and Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI
2	Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI
3	Levi F, Pasche C, Lucchini F and La Vecchia C: Diabetes mellitus, family history, and colorectal cancer. J Epidemiol Community Health. 56:479–480. 2002. View Article : Google Scholar : PubMed/NCBI
4	Giouleme O, Diamantidis MD and Katsaros MG: Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol. 17:444–448. 2011. View Article : Google Scholar : PubMed/NCBI
5	Pechlivanis S, Bermejo JL, Pardini B, et al: Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol. 160:933–940. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kobayashi M, Ohno T, Tsuchiya T and Horio F: Characterization of diabetes-related traits in MSM and JF1 mice on high-fat diet. J Nutr Biochem. 15:614–621. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ezzat VA, Duncan ER, Wheatcroft SB and Kearney MT: The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 10:198–211. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ooi GT, Tseng LY, Tran MQ and Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol. 6:2219–2228. 1992.PubMed/NCBI
9	Guastamacchia E, Resta F, Triggiani V, et al: Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord. 4:59–66. 2004. View Article : Google Scholar
10	Lee CT, Park KH, Adachi Y, et al: Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther. 10:57–63. 2003. View Article : Google Scholar
11	Bai HZ, Pollman MJ, Inishi Y and Gibbons GH: Regulation of vascular smooth muscle cell apoptosis: Modulation of bad by a phosphatidylinositol 3-kinase-dependent pathway. Circ Res. 85:229–237. 1999. View Article : Google Scholar : PubMed/NCBI
12	Matsui T, Li L, del Monte F, et al: Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 100:2373–2379. 1999.
13	Ibrahim YH and Yee D: Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res. 14:261–269. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kohda M, Hoshiya H, Katoh M, et al: Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol Carcinog. 31:184–191. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG and Ma T: Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol. 9:974–977. 2003.PubMed/NCBI
16	Minagawa N, Nakayama Y, Hirata K, et al: Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res. 22:2957–2963. 2002.PubMed/NCBI
17	Hashim AF, Al-Janabi AA, Mahdi LH, Al-Toriahi KM and Yasseen AA: Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer. Libyan J Med. 5:2010. View Article : Google Scholar
18	Chang CK and Ulrich CM: Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia. 46:595–607. 2003.PubMed/NCBI
19	Grulich-Henn J, Ritter J, Mesewinkel S, Heinrich U, Bettendorf M and Preissner KT: Transport of insulin-like growth factor-1 across endothelial cell monolayers and its binding to the subendothelial matrix. Exp Clin Endocrinol Diabetes. 110:67–73. 2002. View Article : Google Scholar : PubMed/NCBI